• Publications
  • Influence
Benzodiazepine prescribing to the Swiss adult population: results from a national survey of community pharmacies
TLDR
Benzodiazepine prescriptions were appropriate for most patients and thus were prescribed in therapeutic doses, as indicated in the treatment guidelines, but on the other hand, the survey showed that 1.6% of the patients had prescriptions for long time periods at very high doses, indicating an abuse or dependence on benzodiazepines in this subgroup. Expand
Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine.
TLDR
After eight weeks, both active drugs-phenelzine somewhat more than moclobemide--were clinically and statistically significantly more effective than placebo, as assessed by rating scales. Expand
Moclobemide in elderly patients with cognitive decline and depression: an international double-blind, placebo-controlled trial.
TLDR
Moclobemide was shown to be a safe, well tolerated and effective antidepressant, which did not cause impairment of cognitive function in elderly patients with a DSM- III diagnosis of dementia and/or DSM-III major depression. Expand
Evaluation of the efficacy and safety of flumazenil in the treatment of portal systemic encephalopathy: a double blind, randomised, placebo controlled multicentre study.
TLDR
A subgroup of patients with PSE resulting from chronic liver disease may benefit from the administration of flumazenil, which was well tolerated and showed clinically relevant improvement in the PSE score. Expand
Moclobemide is effective and well tolerated in the long-term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder
TLDR
In a large sample of social anxiety disorder patients with and without comorbid anxiety disorders, moclobemide was both effective and well-tolerated in the short as well as long-term, and strengthen the range of therapeutic options for managing this important disorder. Expand
Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease
TLDR
The efficacy of acetyl-L-carnitine in mild cognitive impairment (MCI) and mild (early) Alzheimer's disease (AD) was investigated with a meta-analysis of double-blind, placebo-controlled prospective, parallel group comparison studies. Expand
Efficacy and Tolerability of Moclobemide in Comparison with Placebo, Tricyclic Antidepressants, and Selective Serotonin Reuptake Inhibitors in Elderly Depressed Patients: A Clinical Overview
TLDR
Moclobemide is an effective and well-tolerated antidepressant for the treatment of elderly depressed patients and of similar efficacy to the TCAs and the more recently introduced SSRIs. Expand
Pharmacology of flumazenil
TLDR
The existence of flumazenil is important, with implications for future research and the development of minimally invasive therapy and day‐case surgery, and with increasing pressures on non‐anaesthetically trained practitioners to perform sedation, it has important implications for safety. Expand
Moclobemide and tricyclic antidepressants in severe depression: meta-analysis and prospective studies.
TLDR
The results of this analysis failed to reveal any difference in efficacy between moclobemide and imipramine in any subgroup of hospitalized depressives, including patients in the highest HAM-D severity band and psychotic patients. Expand
Monoamine oxidase inhibitors, cognitive functions and neurodegenerative diseases.
TLDR
The rational for using selegiline as a neuroprotector in Parkinson's disease may also be applicable in Alzheimer's disease in which a dramatic increase in the MAO-B activity has been reported. Expand
...
1
2
3
4
5
...